Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 08 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-2.10 Insider Own56.71% Shs Outstand11.82M Perf Week-2.91%
Market Cap46.40M Forward P/E- EPS next Y-1.31 Insider Trans0.00% Shs Float10.04M Perf Month21.95%
Income-33.78M PEG- EPS next Q-0.28 Inst Own28.19% Short Float / Ratio1.63% / 0.37 Perf Quarter58.73%
Sales42.14M P/S1.10 EPS this Y20.59% Inst Trans-0.10% Short Interest0.16M Perf Half Y-11.89%
Book/sh-1.83 P/B- EPS next Y30.42% ROA-56.32% Target Price4.50 Perf Year-43.21%
Cash/sh0.63 P/C3.20 EPS next 5Y- ROE-775.14% 52W Range1.10 - 5.38 Perf YTD-52.94%
Dividend- P/FCF- EPS past 5Y-21.70% ROI-2647.49% 52W High-62.83% Beta0.45
Dividend %- Quick Ratio0.73 Sales past 5Y6.05% Gross Margin35.94% 52W Low81.82% ATR0.20
Employees164 Current Ratio0.87 Sales Q/Q-50.54% Oper. Margin-50.19% RSI (14)59.61 Volatility14.23% 10.94%
OptionableNo Debt/Eq- EPS Q/Q21.04% Profit Margin-80.17% Rel Volume0.26 Prev Close2.00
ShortableYes LT Debt/Eq- EarningsNov 13 AMC Payout- Avg Volume448.06K Price2.00
Recom1.00 SMA2011.86% SMA5032.01% SMA2000.00% Volume117,883 Change0.00%
Date Action Analyst Rating Change Price Target Change
Nov-02-20Initiated Truist Buy $20
Nov-02-20Initiated Piper Sandler Overweight $20
Nov-02-20Initiated Cowen Outperform $20
Nov-02-20Initiated Cantor Fitzgerald Overweight $20
Nov-13-23 04:05PM
Nov-09-23 08:30AM
Nov-06-23 04:05PM
Oct-18-23 08:00AM
Sep-20-23 08:30AM
08:36AM Loading…
Sep-19-23 08:36AM
Sep-18-23 04:08PM
Sep-08-23 08:30AM
Sep-06-23 04:05PM
Aug-30-23 08:30AM
Aug-21-23 09:42AM
Aug-15-23 05:21AM
Aug-14-23 04:05PM
Jul-31-23 04:05PM
Jul-26-23 03:29PM
04:05PM Loading…
Jul-17-23 04:05PM
Jul-13-23 04:30PM
May-19-23 01:45PM
May-13-23 08:17AM
May-11-23 09:58AM
May-10-23 04:05PM
May-03-23 04:05PM
Apr-20-23 04:30PM
Apr-17-23 06:11AM
Apr-05-23 09:55AM
Mar-27-23 06:26AM
Mar-23-23 06:08AM
04:01PM Loading…
Mar-22-23 04:01PM
Mar-20-23 12:01PM
Mar-15-23 04:05PM
Feb-27-23 08:15AM
Jan-31-23 08:00AM
Jan-26-23 12:00PM
Jan-21-23 09:58AM
Jan-09-23 08:15AM
Dec-15-22 08:00AM
Dec-10-22 07:38AM
Dec-01-22 09:04AM
Nov-30-22 04:08PM
Nov-21-22 04:05PM
Nov-16-22 06:00AM
Nov-14-22 05:25PM
Nov-07-22 04:05PM
Oct-25-22 09:47AM
Oct-24-22 08:00AM
Oct-18-22 04:05PM
Oct-11-22 04:35PM
Aug-26-22 09:00AM
Aug-17-22 04:05PM
Aug-16-22 01:53PM
Aug-14-22 10:16AM
Aug-11-22 04:05PM
Aug-10-22 06:56PM
Aug-09-22 05:58PM
Jul-28-22 04:05PM
Jul-20-22 09:40AM
Jun-27-22 04:15AM
Jun-21-22 04:05PM
Jun-01-22 08:50AM
May-09-22 05:25PM
May-02-22 08:21AM
Apr-25-22 04:05PM
Apr-12-22 04:05PM
Apr-04-22 08:00AM
Mar-31-22 06:50PM
Mar-11-22 08:30AM
Mar-07-22 06:40AM
Mar-04-22 09:28AM
Mar-03-22 06:25PM
Feb-23-22 04:01PM
Feb-17-22 04:01PM
Feb-14-22 12:00PM
Jan-18-22 08:45AM
Jan-11-22 10:00AM
Dec-27-21 04:01PM
Dec-08-21 05:31PM
Dec-06-21 06:59AM
Nov-15-21 04:05PM
Nov-09-21 05:25PM
Nov-02-21 03:02PM
Oct-26-21 08:30AM
Oct-25-21 04:01PM
Sep-15-21 04:05PM
Aug-31-21 04:05PM
Aug-15-21 03:05AM
Aug-09-21 04:01PM
Elutia, Inc. operates as a biotechnology company. It develops biologic products to improve compatibility between medical devices and the patients who need them. The firm operates through the following segments: Device Protection, Women's Health, Orthobiologics and Cardiovascular. The Device Protection segment includes biological envelope that remodels into systematically connected, vascularized tissue for the long-term pocket protection of certain cardiac and neurostimulator implantable electronic vehicles. The Women's Health segment includes pre-hydrated, human acellular dermal matrix, or HADM, that is designed to enable rapid integration, cellular repopulation and rapid revascularization at the surgical site. The Orthobiologics segment includes a variety of viable matrices, produced with a proprietary process that is designed to protect and preserve native bone cells and reduce programmable cell death, for use in bone repair and fusion procedures. The Cardiovascular segment includes a portfolio of extracellular matrices that retain the natural composition of collagen, growth factors and proteins for use in vascular and cardiac repair and pericardial closure. The company was founded by Kevin L. Rakin and Charles Randal Mills on August 6, 2015 and is headquartered in Silver Spring, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mills C RandalPRESIDENT AND CEOApr 27Option Exercise0.0044,947048,008Apr 28 05:31 PM
Birchview Capital, LP10% OwnerMar 27Buy1.5910,00015,8701,655,184Mar 27 04:17 PM
Birchview Capital, LP10% OwnerMar 24Buy1.3520,00027,0781,645,184Mar 27 04:17 PM
Birchview Capital, LP10% OwnerMar 23Buy1.49110,000164,0101,625,184Mar 27 04:17 PM
Englese ThomasCHIEF COMMERCIAL OFFICERMar 09Sale4.302891,24317,917Mar 09 09:18 PM
Englese ThomasCHIEF COMMERCIAL OFFICERMar 08Option Exercise0.00937018,206Mar 09 09:18 PM
Ferguson MatthewCHIEF FINANCIAL OFFICERMar 08Option Exercise0.001,287046,504Mar 09 09:11 PM
Colpman DavidDirectorDec 15Buy3.903,09812,0823,098Dec 16 04:46 PM
Makes BrigidDirectorDec 09Buy3.652,0007,3002,000Dec 12 05:08 PM